Thalidomide for Patients with Recurrent Lymphoma

Cancer

Volumn 100, Issue 6, 2004, Pages 1186-1189

  Pro, Barbara ^a   Younes, Anas ^a   Albitar, Maher ^a   Dang, Nam H ^a   Samaniego, Felipe ^a   Romaguera, Jorge ^a   McLaughlin, Peter ^a   Hagemeister, Fredrick B ^a   Rodriguez, Maria A ^a   Clemons, Marilyn ^a   Cabanillas, Fernando ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Hodgkin disease; Multiple myeloma; Non Hodgkin disease; Single agent activity; Thalidomide

Indexed keywords

ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; PREDNISONE; RITUXIMAB; SCATTER FACTOR; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VINCRISTINE SULFATE;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; DISEASE COURSE; DOSE RESPONSE; DRUG ACTIVITY; EVIDENCE BASED MEDICINE; FATIGUE; HODGKIN DISEASE; HUMAN; LYMPHATIC SYSTEM TUMOR; LYMPHOMA; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RECURRENT CANCER; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STOMACH MUCOSA;

ADULT; AGED; ANGIOGENESIS INHIBITORS; CYTOKINES; HUMANS; LYMPHOMA; MIDDLE AGED; RECURRENCE; SALVAGE THERAPY; THALIDOMIDE; TREATMENT OUTCOME;

EID: 12144291465     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20070     Document Type: Article

References (8)

1. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91:4082-4085.
2. Drake MJ, Robson W, Mehta P, Schofield I, Neal DE, Leung HY. An open-label Phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer. 2003;88:822-827.
3. Baidas SM, Winer EP, Fleming GF, et al. Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Clin Oncol. 2000;18:2710-2717.
4. Bertolini F, Mingrone W, Alietti A, et al. Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. Ann Oncol. 2001;12:987-990.
5. Piccaluga PP, Visani G, Pileri SA, et al. Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study. Leukemia. 2002;16:1609-1614.
6. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565-1571.
7. Drach J, Kaufmann H, Puespoek A, et al. Marked antitumor activity of rituximab plus thalidomide in patients with relapsed/resistant mantle cell lymphoma [abstract]. Blood. 2002;100:606a.
8. Arrieta O, Guevara P, Tamariz J, Rembao D, Rivera E, Sotelo J. Antiproliferative effect of thalidomide alone and combined with carmustine against C6 rat glioma. Int J Exp Pathol. 2002;83:99-104.